Akebia Therapeutics is a biopharmaceutical company that develops and commercializes innovative treatments for kidney disease. The company's primary marketed products are Vafseo, an oral medication for treating anemia in dialysis patients, and Auryxia, used to control phosphorus levels and treat iron deficiency anemia in chronic kidney disease patients; both are sold directly to dialysis organizations and through wholesale distributors, with international revenue generated through licensing partnerships. Akebia serves a large market of kidney disease patients through established relationships with major dialysis providers and generates revenue from product sales and royalties on international partner sales and milestones.